Brunet Hannah E, Miller Justin B, Shi Jiong, Chung Briana, Munter Bryce Taylor, Sabbagh Marwan Noel
Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV.
Barrow Neurological Institute, Phoenix, AZ.
Alzheimers Dement (Amst). 2019 Jun 6;11:424-429. doi: 10.1016/j.dadm.2019.04.004. eCollection 2019 Dec.
Researchers are searching for clinical instruments to predict amyloid positivity for disease classification. Informant-based reports could detect disease status. This study compares subjective memory complaints captured by informant-based reports between positron emission tomography (PET)-positive and PET-negative patients and hypothesizes that amyloid PET positivity associates with increased informant-based cognitive complaints.
Ninety-eight amnestic mild cognitive impairment or mild dementia subjects were studied. Subjective report was captured by the informant-driven Alzheimer's Questionnaire (AQ) administered before PET. Differences in demographics and AQ score by diagnostic status and amyloid status were measured, and a receiver-operating characteristic curve was calculated.
Sixty-five mild cognitive impairment/Alzheimer's disease amyloid PET-positive and 33 amyloid PET-negative subjects were included. AQ was significantly higher (12.51 ± 4.95) for amyloid PET-positive subjects (9.06 ± 3.65; = .001).
Amyloid PET-positive subjects with Alzheimer's disease or mild cognitive impairment have more informant-based reports of cognitive decline, indicating utility for a brief informant measure.
研究人员正在寻找用于疾病分类的预测淀粉样蛋白阳性的临床工具。基于 informant 的报告可以检测疾病状态。本研究比较了正电子发射断层扫描（PET）阳性和 PET 阴性患者基于 informant 的报告所捕获的主观记忆主诉，并假设淀粉样蛋白 PET 阳性与基于 informant 的认知主诉增加相关。
对 98 名遗忘型轻度认知障碍或轻度痴呆患者进行了研究。主观报告通过在 PET 检查前由 informant 驱动的阿尔茨海默病问卷（AQ）获取。测量了不同诊断状态和淀粉样蛋白状态下的人口统计学差异和 AQ 评分，并计算了受试者操作特征曲线。
纳入了 65 名轻度认知障碍/阿尔茨海默病淀粉样蛋白 PET 阳性患者和 33 名淀粉样蛋白 PET 阴性患者。淀粉样蛋白 PET 阳性患者的 AQ 显著更高（12.51 ± 4.95）（9.06 ± 3.65；P = 0.001）。
患有阿尔茨海默病或轻度认知障碍的淀粉样蛋白 PET 阳性患者有更多基于 informant 的认知衰退报告，表明简短的 informant 测量方法具有实用性。
